Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 26 Urinary Bladder Neoplasms 17 Carcinoma, Non-Small-Cell Lung 17 Lung Neoplasms 13 Ovarian Neoplasms 10 Nasopharyngeal Carcinoma 9 Biliary Tract Neoplasms 8 Non-Muscle Invasive Bladder Neoplasms 7 Neoplasm Metastasis 7 Cholangiocarcinoma 7 Lymphoma, Large B-Cell, Diffuse 6 Triple Negative Breast Neoplasms 5 Colorectal Neoplasms 5 Breast Neoplasms 5 Recurrence 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Neoplasms 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Carcinoma, Transitional Cell 4 Osteosarcoma 3 Melanoma 3 Lymphoma, Non-Hodgkin 3 Uterine Cervical Neoplasms 2 Urologic Neoplasms 2 Rectal Neoplasms 2 Lymphoma, Follicular 2 Lymphoma, B-Cell 2 Gallbladder Neoplasms 2 Colonic Neoplasms 2

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × Gemcitabine × 30 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡